

## **Theralase's Photo Dynamic Compounds (PDCs) Effective in Destruction of Cancerous Tumours in an *In-vivo* Model**

### **Theralase's Patented PDCs Have Successfully Achieved Efficacy *In-vivo***

Toronto, Ontario – November 29, 2011, Theralase Technologies Inc. (TSX-V: TLT) announced today it has successfully destroyed cancer cells in an *in-vivo* subcutaneous malignant tumour model. These results now confirm in a well established *in-vivo* model what has been demonstrated previously in *in-vitro* cancer cell lines model, which is a high kill rate of cancer cells when exposed to Theralase's patented light activated PDCs.

Dr. Lothar Lilge, PhD, Senior Scientist at the Ontario Cancer Institute, Princess Margaret Hospital stated, "It was critical to establish the relevance of prior successful *in-vitro* destruction for three cancer cell lines at greater than 99% efficacy to a subcutaneous *in-vivo* tumour model to see if similar results could be achieved. The results in this model of the first Photo Dynamic Compound (PDCs) tested demonstrates significant destruction of tumours in this model, exemplified by histology showing tumour necrosis and wide spread eradication of the cancer cells. These results support the high therapeutic potential of Theralase's patented Type 1 PDCs towards cancer destruction *in-vivo*. We continue to work towards increasing the efficacy by optimizing the laser source emission utilized in the activation of the PDCs."

Dr. Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer at Theralase Inc., said, "We have made a large advancement towards the understanding of the mechanism by which our patented PDCs can be utilized to effectively destroy cancerous tumours in an established *in-vivo* subcutaneous cancer model. This is a very significant milestone in our Research and Development path, proving that Theralase's Photo Dynamic Compounds (PDCs), which use a virtually non-toxic photosensitizer activated by visible light can achieve local destruction of malignant tumour *in-vivo*. We are planning to present these exciting results at the annual SPIE International Society for Optics and Photonics conference in 2012."

Roger Dumoulin-White, President and CEO of Theralase Inc. expressed, "Theralase is excited that our patented PDCs have successfully achieved efficacy in an *in-vivo* subcutaneous model. This is an important milestone for the Company because we have now demonstrated the ability of the patented PDCs to destroy cancer cells in both an *in-vitro* and in an *in-vivo* cancer model, when light activated. The therapy with the Theralase PDC compound was well tolerated by the host. Theralase is well on its way to prove the viability of its technology to increase the oncologist's options for a successful treatment of cancer. What our skilled scientific and preclinical researchers have unveiled today is nothing short of the fact that the first Theralase PDC tested *in-vivo* from our library of compounds is effective both *in-vitro* and *in-vivo*."

There is an earnings conference call and corporate update scheduled for November 30th, 2011 at 9:00am ET. The call in number is 1-866-440-8936, the conference ID is 8791351#. The call will be hosted by Roger Dumoulin-White, President & CEO of Theralase Technologies Inc.

## About Theralase Technologies Inc.

Theralase Technologies Inc. founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound healing. When combined with its patented, light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria, viruses as well as microbial pathogens associated with food contamination. For further information please visit [www.thermalase.com](http://www.thermalase.com), regulatory filings may be viewed by visiting [www.sedar.com](http://www.sedar.com).

*This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.*

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.*

For More Information or Media Opportunities Please Contact:

Roger Dumoulin-White  
President & CEO,  
416-447-8455 ext. 225  
[rwhite@thermalase.com](mailto:rwhite@thermalase.com)

Greg Bewsh  
Director of Investor Relations,  
416-447-8455 ext. 262  
[gbewsh@thermalase.com](mailto:gbewsh@thermalase.com)